quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:02:00·45d
PRRelease
Vertex Pharmaceuticals Incorporated logo

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

VRTX· Vertex Pharmaceuticals Incorporated
Health Care
Original source

Companies

  • VRTX
    Vertex Pharmaceuticals Incorporated
    Health Care

Recent analyst ratings

  • Mar 18UpdateMaxim Group$575.00
  • Mar 10UpdateJefferies$580.00
  • Mar 10UpdateOppenheimer$600.00
  • Feb 13UpdateOppenheimer$540.00
  • Jan 28UpdateBarclays$606.00
  • Jan 22UpdateRBC Capital Mkts$546.00

Related

  • INSIDER6d
    SEC Form 4 filed by Upadhyay Suketu
  • INSIDER6d
    SEC Form 4 filed by Sachs Bruce I
  • INSIDER6d
    SEC Form 4 filed by Garber Alan M
  • PR13d
    Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
  • PR17d
    Vertex to Announce First Quarter 2026 Financial Results on May 4th
  • INSIDER20d
    SEC Form 4 filed by Liu Joy
  • SEC21d
    SEC Form DEFA14A filed by Vertex Pharmaceuticals Incorporated
  • SEC21d
    SEC Form DEF 14A filed by Vertex Pharmaceuticals Incorporated
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022